000 02374nam a2200493 i 4500
999 _c291788
_d291788
001 on1140549210
003 OCoLC
005 20200313193136.0
007 he bmb024bbca
008 200213s2019 dcu b f000 0 eng c
040 _aPUCPR
_beng
_erda
_cGPO
_dMvI
042 _apcc
043 _an-us---
074 _a1016-B (MF)
086 0 _aY 4.OV 2:116-24
088 _aSerial no. 116-24 (United States. Congress. House. Committee on Oversight and Reform)
099 _aY 4.OV 2:116-24
110 1 _aUnited States.
_bCongress.
_bHouse.
_bCommittee on Oversight and Reform,
245 1 0 _aHIV prevention drug :
_bbillions in corporate profits after millions in taxpayer investments : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, May 16, 2019.
246 3 _aHuman Immunodeficiency Virus prevention drug
246 3 0 _aBillions in corporate profits after millions in taxpayer investments
264 1 _aWashington :
_bU.S. Government Publishing Office,
_c2019.
300 _aiii, 63 pages ;
_c24 cm
336 _btxt
337 _bh
_2rdamedia
338 _bhe
_2rdacarrier
500 _a"Serial no. 116-24."
500 _aShipping list no.: 2020-0010-M.
500 _aGPO Cataloging Record Distribution Program (CRDP).
533 _aMicrofiche.
_b[Washington, D.C.] :
_cU.S. Government Printing Office,
_d[2019]
_e1 microfiche : negative.
776 0 8 _iPrint version:
_aUnited States. Congress. House. Committee on Oversight and Reform.
_tHIV prevention drug
_w(DLC) 2019394984
_w(OCoLC)1112356798
776 0 8 _iOnline version:
_aUnited States. Congress. House. Committee on Oversight and Reform.
_tHIV prevention drug
_w(OCoLC)1112074275
050 4 _aKF27
_b.O96 2019i
610 2 0 _aGilead Sciences (Firm)
650 0 _aPre-exposure prophylaxis
_xPrices
_zUnited States.
650 0 _aPre-exposure prophylaxis
_zUnited States
_xCost control.
650 0 _aHIV infections
_zUnited States
_xPrevention.
650 0 _aPrescription pricing
_xGovernment policy
_zUnited States.
650 0 _aPharmaceutical industry
_xPrices
_xGovernment policy
_zUnited States.
650 0 _aMedical policy
_zUnited States.
650 0 _aFederal aid to medical research
_zUnited States.
655 7 _aLegislative hearings.
_2lcgft
942 _2sudocs
_c8